Home » Topics » BioWorld Science

BioWorld Science
RSS

Enrollment completed in ADHD phase II study of NS-2359

May 27, 2004

Pexelizumab reduces events in patients undergoing CABG

May 27, 2004

Liraglutide shows promise in type 2 diabetes

May 27, 2004

Vertex plans METRO study for merimepodib

May 27, 2004

Xanafide enters phase I/II study for metastatic prostate cancer

May 27, 2004

R-115777 active but poorly tolerated in MDS; does not prolong survival with gemcitabine

May 27, 2004

Juvaris enters licensing agreement for new therapeutic vaccine platform

May 27, 2004

Schering-Plough reviews option for intranasal pleconaril

May 27, 2004

DX-88 development placed on hold pending preclinical review

May 27, 2004

Enrollment completed in STELLAR 4 trial of Xyotax

May 27, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...